Advertisement

Aberrant Expression of Sialidase in Cancer and Diabetes

  • Taeko Miyagi

Abstract

Altered sialylation is associated with malignant properties such as invasiveness and metastasis. To understand the causes and the consequences of aberrant forms, our studies have focused on sialidases responsible for the removal of sialic acids from glycoproteins and glycolipids. Mammalian sialidases have been classified into four types (designated as Neu1, Neu2, Neu3, and Neu4) differing in subcellular localization and enzymatic properties. We found that the four types behave in different manners during carcinogenesis (Miyagi et al. 2004). Among the sialidases, Neu3 is a key enzyme for ganglioside degradation and is unique in being localized mainly in the plasma membrane and in hydrolyzing specifically gangliosides, thereby probably participating in cell surface events including neuronal differentiation and transmembrane signaling. The human Neu3 ortholog, NEU3, is indeed upregulated in various cancers where it suppresses apoptosis. Its overexpression in mice results in a diabetic phenotype. Herein molecular mechanisms and significance of aberrant expression of NEU3 are briefly introduced.

Keywords

Sialic Acid Insulin Signaling Sodium Butyrate Diabetic Phenotype Malignant Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kakugawa Y, Wada T, Yamaguchi K, Yamanami H, Ouchi K, Sato I, Miyagi T (2002) Up-regulation of plasma membrane-associated ganglioside sialidase (Neu 3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci 99:10718–10723PubMedCrossRefGoogle Scholar
  2. Miyagi T, Wada T, Yamaguchi K, Hata K (2004) Sialidase and malignancy: a minireview. Glycoconjugate J 20:189–198CrossRefGoogle Scholar
  3. Sasaki A, Hata H, Suzuki S, Sawada M, Wada T, Yamaguchi K,. Obinata M, Tateno H, Suzuki Y, Miyagi T (2003) Overexpression of plasma membrane-associated sialidase attenuates insulin signaling in transgenic mice. J Biol Chem 278:27896–27902PubMedCrossRefGoogle Scholar
  4. Ueno S, Saito S, Wada T, Yamaguchi K, Satoh M, Arai Y, Miyagi T (2006) Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes the interleukin-6-induced apoptosis suppression and cell motility. J Biol Chem 281:7756–7764PubMedCrossRefGoogle Scholar
  5. Wada T, Hata K, Yamaguchi K, Shiozaki K, Koseki K, Moriya S, Miyagi T (2007) A crucial role of plasma membrane-associated sialidase (NEU3) in the survival of human cancer cells. Oncogene 26:2483–2490PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Taeko Miyagi
    • 1
  1. 1.Division of BiochemistryMiyagi Cancer Center Research InstituteNatori, MiyagiJapan

Personalised recommendations